Steady-state gadofosveset-enhanced dark lumen MR-enterography

Ceska Radiologie

Volumn 63, Issue 4, 2009, Pages 315-321

  Ferda, Jiří ^a   Mirka, Hynek ^a   Koželuhová, Jana ^a   Kastner, Jan ^a   Baxa, Jan ^a   Ferdová, Eva ^a   Daum, Ondřej ^a   Třeška, Vladislav ^a   Kreuzberg, Boris ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Blood pool contrast agent; Crohn's disease; Gadofosveset; MR enterography

Indexed keywords

GADOFOSVESET;

ABSCESS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG DISTRIBUTION; FEMALE; HUMAN; ILEUM; IMAGE ANALYSIS; INTESTINE FISTULA; MAGNETIC RESONANCE ENTEROGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; STEADY STATE;

EID: 76149106509     PISSN: 12107883     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Maglinte DD, Siegelman ES, Kelvin FM. MR enteroclysis: the future of small-bowel imaging? Radiology 2000; 215: 639-641.
2. Umschaden HW, Szolar D, Gasser J, Umschaden M, Haselbach H. Small-bowel disease: comparison of MR enteroclysis images with conventional enteroclysis and surgical findings. Radiology 2000; 215: 717-725.
3. Schmidt S, Lepori D, Meuwly JY, Duvoisin B, Meuli R, Michetti P, Felley C, Schnyder P, van Melle G, Denys A. Prospective comparison of MR enteroclysis with multidetector spiral-CT enteroclysis: interobserver agreement and sensitivity by means of "sign-by-sign" correlation. Eur Radiol. 2003; 13: 1303-1311.
4. Gourtsoyiannis NC, Grammatikakis J, Papamastorakis G, Koutroumbakis J, Prassopoulos P, Rousomoustakaki M, Papanikolaou N. Imaging of small intestinal Crohn's disease: comparison between MR enteroclysis and conventional enteroclysis. Eur Radiol. 2006; 16: 1915-1925.
5. Negaard A, Paulsen V, Sandvik L, Berstad AE, Borthne A, Try K, Lygren I, Storaas T, Klow NE. A prospective randomized comparison between two MRI studies of the small bowel in Crohn's disease, the oral contrast method and MR enteroclysis. Eur Radiol 2007; 17: 2294-2301.
6. Masselli G, Casciani E, Polettini E, Gualdi G. Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease. Eur Radiol 2007; [Epub ahead of print).
7. Lohan D, Cronin C, Meehan C, Alhajeri AN, Roche C, Murphy J. MR small bowel enterography: optimization of imaging timing. Clin Radiol 2007; 62: 804-807.
8. Godefroy C, Pilleul F, Dugougeat F, Yzèbe D, Lachaux A, Pracros JP, Valette PJ. Value of contrast-enhanced MR enterography in pediatric Crohn's disease: preliminary study. J Radiol 2005; 86: 1685-1692.
9. Koh DM, Miao Y, Chinn RJ, Amin Z, Zeegen R, Westaby D, Healy JC. MR imaging evaluation of the activity in Crohn's disease. AJR 2001; 177: 1325-1332.
10. Maccioni F, Bruni A, Viscido Colaiacomo MC, Cocco A, Montesani C, Caprilli R, Marini M. MR imaging in patients with Crohn's disease: value of T2-versus T1-weighted gadolinium enhances MR sequences with use of an oral superparamagnetic contrast agent. Radiology 2006; 238: 517-530.
11. Parmelee DJ, Walovitch RC, Ouellet HS, Lauffer RB. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood-pool agent for magnetic resonance imaging. Invest Radiol 1997; 32: 741-747.
12. Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Wallowitch RC. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998; 207: 529-538.
13. Henness S, Keating GM. Gadofosveset. Drugs 2006; 66: 851-857.
14. Shamshi K, Yucel EK, Chamberlin P. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase-II and phase-III clinical trials data. Invest Radiol 2006; 41:822-830.
15. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843-846.
16. Rohrer M, Geerts-Ossevoort L, Laub G. Technical requirements, biophysical considerations and protocol optimization with magnetic resonance angiography using blood-pool agents. Eur Radiol Suppl 2007; 17: B7-B12.
17. Eldredge HB, Spiller M, Chasse JM, Greenwood MT, Caravan P. Species dependence of plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol 2006; 41: 229-243.
18. Herborn CU, Waldschuetz R, Lauenstein TC, et al. Contrast-enhanced magnetic resonance imaging (MS-325) in a murine model of systemic lupus erythematosus. Invest Radiol 2002; 37: 464-469.
19. Herborn CU, Lauenstein TC, Voght FM, Lauffer RB, Debatin JF, Ruehm SG. Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model. AJR 2002; 179: 1567-1572.
20. Dewey M, Kaufels N, Laute M, Schnorr J, Raynaud JS, Hamm B, Taupitz M. Magnetic resonance imaging of myocardial perfusion and viability using a blood pool contrast agent. Invest Radiol 2004; 39: 498-505.